Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Université de Montréal

$12,468.00

Dopamine supersensitivity following chronic anti-dopaminergic treatment

EF 2014-15

Résumé
The dopamine (DA) system is critical for normal, everyday behaviours including eating, procreation and movement, but abnormal DA function is linked to a number of psychiatric disorders including psychosis and drug addiction. The most widely-used animal model of DA hyperactivity involves repeated stimulation of the DA system via administration of DA agonists (e.g., amphetamine) and this model has helped researchers to better understand DA function under normal and abnormal conditions. However, chronic suppression of the DA system (for example, via blockade of DA D2/3 receptors) also induces a DA hyperactive state. This alternate model of DA supersensitivity is an ideal tool to further our understanding of the DA system and its function. However, little is known about the long-term behavioural consequences of chronic DA receptor blockade or about the neurobiological processes involved in the induction of DA supersensitivity under these conditions. The primary goal of the proposed research, therefore, is to use animal models to determine the effects of chronic DA D2/3 receptor blockade on DA-dependent behaviours and to explore potential underlying mechanisms. This will be achieved by treating rats with the DA D2/3 receptor antagonist haloperidol and measuring their behavioural response in commonly-used tests of DA function, including psychomotor sensitization, intravenous drug self-administration and operant responding for conditioned reward. Prior research suggests that increased activity within a specific population of neurons that express the neuropeptide enkephalin and form the striatopallidal pathway might be a common mechanism underlying the ability of either DA agonists or DA D2/3 receptor antagonists to induce a DA supersensitive state. Therefore, I will determine whether the effects of haloperidol treatment on the DA-dependent behaviour mentioned above involve increased activity within the enkephalin/striatopallidal pathway. As such, these results will increase our basic understanding of the functions subserved by the DA system and allow us to better predict outcome when DA function is abnormal.
Programme
Discovery Grants Program - Individual
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
355923-2008
Name nom
Samaha, AnneNoel
Department département
Pharmacologie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2008
Award amount
12468
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
12
Committee name en
Psychology: Brain, Behaviour & Cognitive Sciences
Committee name fr
Psychologie: Cerveau, comportement et science cognitive
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
6310
Research subject group en
Psychology
Research subject group fr
Psychologie
Research subject en
Behavioural neuroscience --reward, motivation
Research subject fr
Neurologie du comportement --récompense, motivation
Partie
7
Nb partie
7
Application title
Dopamine supersensitivity following chronic anti-dopaminergic treatment
Keyword
NSERC
Application summary
The dopamine (DA) system is critical for normal, everyday behaviours including eating, procreation and movement, but abnormal DA function is linked to a number of psychiatric disorders including psychosis and drug addiction. The most widely-used animal model of DA hyperactivity involves repeated stimulation of the DA system via administration of DA agonists (e.g., amphetamine) and this model has helped researchers to better understand DA function under normal and abnormal conditions. However, chronic suppression of the DA system (for example, via blockade of DA D2/3 receptors) also induces a DA hyperactive state. This alternate model of DA supersensitivity is an ideal tool to further our understanding of the DA system and its function. However, little is known about the long-term behavioural consequences of chronic DA receptor blockade or about the neurobiological processes involved in the induction of DA supersensitivity under these conditions. The primary goal of the proposed research, therefore, is to use animal models to determine the effects of chronic DA D2/3 receptor blockade on DA-dependent behaviours and to explore potential underlying mechanisms. This will be achieved by treating rats with the DA D2/3 receptor antagonist haloperidol and measuring their behavioural response in commonly-used tests of DA function, including psychomotor sensitization, intravenous drug self-administration and operant responding for conditioned reward. Prior research suggests that increased activity within a specific population of neurons that express the neuropeptide enkephalin and form the striatopallidal pathway might be a common mechanism underlying the ability of either DA agonists or DA D2/3 receptor antagonists to induce a DA supersensitive state. Therefore, I will determine whether the effects of haloperidol treatment on the DA-dependent behaviour mentioned above involve increased activity within the enkephalin/striatopallidal pathway. As such, these results will increase our basic understanding of the functions subserved by the DA system and allow us to better predict outcome when DA function is abnormal.